p-Index From 2021 - 2026
0.562
P-Index
This Author published in this journals
All Journal Jurnal Respirasi (JR)
Iin Noor Chozin
Dr. Saiful Anwar General Hospital, Malang, Indonesia.

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

Persistent Pneumothorax in Neurofibromatosis Type-1 Hustorio Aliongko Simamora; Susanthy Djajalaksana; Iin Noor Chozin; Dini Rachma Erawati; Hendy Setyo Yudhanto; Gracelia Ruth Elisabeth Damanik; Adinda Amalia Dani; Aditya Sri Listyoko
Jurnal Respirasi Vol. 12 No. 1 (2026): January 2026
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v12-I.1.2026.64-70

Abstract

Introduction: Neurofibromatosis type 1 (NF-1) is a rare autosomal dominant disorder. While typically recognized by its cutaneous features, pulmonary involvement, including apical cysts and basal interstitial fibrosis consistent with interstitial lung disease (ILD), can occur in up to 20% of patients. These manifestations create a predisposition to complications such as spontaneous pneumothorax. While this is relatively uncommon, occurring in approximately 1.5% of patients with NF-1, it represents a serious and potentially life-threatening complication when it does occur. Case: A 52-year-old male with a 20-pack-year smoking history and active pulmonary tuberculosis (TB) presented with acute chest pain and dyspnea. Dermatological examination and skin biopsy confirmed the diagnosis of NF-1. A high-resolution computed tomography (HRCT) scan of the chest revealed multiple subpleural pulmonary cysts consistent with NF-1-related ILD, alongside findings suggestive of active TB. The patient was diagnosed with a secondary spontaneous pneumothorax (SSP), which proved to be persistent despite initial chest tube drainage, ultimately requiring surgical intervention. Conclusion: This case highlights that NF-1 is a significant underlying risk factor for persistent pneumothorax, particularly when co-existing with other conditions like active TB and a history of smoking. The chronic inflammation and parenchymal destruction associated with these comorbidities can exacerbate the inherent structural lung abnormalities in NF-1, leading to complex, difficult-to-manage clinical scenarios. Early recognition of pulmonary manifestations in patients with NF-1 is crucial for anticipating and managing severe complications.
Pulmonary Langerhans Cell Histiocytosis: Insights into Pathogenesis, Diagnostic Challenges, and Management Strategies Peter Krisdiyanto; Iin Noor Chozin; Sastia Rakhma
Jurnal Respirasi Vol. 12 No. 3 (2026): September 2026
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v12-I.3.2026.282-291

Abstract

Introduction: Pulmonary Langerhans Cell Histiocytosis (PLCH) is a rare interstitial lung disease strongly linked to cigarette smoking, characterized by nodular and cystic lesions predominantly in the upper and middle lung zones. The disease course is heterogeneous, ranging from spontaneous remission to progressive respiratory failure, with diagnostic and therapeutic challenges requiring a multidisciplinary approach. Methods: This narrative review synthesized evidence from peer-reviewed journals and updated guidelines published in the last decade, emphasizing studies within the past five years. Relevant articles were identified through electronic databases focusing on epidemiology, pathogenesis, diagnostic modalities, and management strategies of PLCH. Results: Cigarette smoke is the main environmental trigger, sustaining Langerhans cell proliferation and chronic inflammation. Molecular studies demonstrate recurrent somatic mutations, particularly BRAF V600E and MAP2K1, confirming PLCH as an inflammatory myeloid neoplasm and supporting targeted therapy. High-resolution computed tomography (HRCT) remains the imaging cornerstone, showing nodular and cystic changes, while histopathology with immunohistochemistry (CD1a, langerin, S100) is the diagnostic gold standard. Pulmonary function testing, bronchoalveolar lavage, and molecular assays add diagnostic precision. Management emphasizes smoking cessation as the primary intervention, with variable outcomes from glucocorticoids and chemotherapy. Targeted therapy with BRAF and MEK inhibitors shows promise in mutation-positive patients, though long-term safety is still under study. For advanced disease, pulmonary hypertension management and lung transplantation are considered. Conclusion: PLCH illustrates the interaction between environmental exposure and molecular oncogenesis. Early diagnosis via HRCT and molecular confirmation is essential, smoking cessation remains central, and ongoing research into biomarkers and targeted interventions may improve personalized outcomes.
Integrated Exhaled Breath VOC Profiling and Serum sICAM-1 for Biomarker Characterization in Drug-Sensitive and Drug-Resistant Tuberculosis Hustorio Aliongko Simamora; Iin Noor Chozin; Ngakan Putu Parsama Putra; Arinto Yudi Ponco Wardoyo; Ani Budi Astuti; Sastia Rakhma
Jurnal Respirasi Vol. 12 No. 3 (2026): September 2026
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v12-I.3.2026.202-211

Abstract

Introduction: Rapid, non-invasive screening for drug-resistant tuberculosis (DR-TB) is urgently needed in high-burden settings such as Indonesia, where sputum-based diagnostics have practical limitations. Integrating exhaled breath volatile organic compounds (VOCs), which reflect host–pathogen metabolic interactions, with serum soluble intercellular adhesion molecule-1 (sICAM-1), a marker of endothelial activation and inflammation, may improve early detection. This study evaluated the combined potential of VOC profiling and sICAM-1 to distinguish drug-sensitive TB (DS-TB), DR-TB, and healthy controls. Methods: A prospective cross-sectional study was conducted in four TB referral hospitals in East Java, Indonesia. Eighty-eight participants were enrolled: DS-TB (n=32), DR-TB (n=30), and healthy controls (n=26). Exhaled breath VOC profiles were analyzed using a breath analyzer, and serum sICAM-1 levels were measured by enzyme-linked immunosorbent assay. Group comparisons used ANOVA or Kruskal–Wallis tests with post hoc analyses, and correlations were assessed using Pearson or Spearman tests. Results: Serum sICAM-1 levels were significantly higher in both TB groups than in controls (p<0.01) but did not differ between DS-TB and DR-TB (p=0.961). Several VOC components differed significantly, particularly formaldehyde, acetone, and methane (CH₄). CH₄ levels were significantly higher in DR-TB than in DS-TB and controls (p<0.05). A weak negative correlation between formaldehyde and sICAM-1 was observed in DS-TB (r = −0.355; p = 0.046). Conclusion: Integrating VOC profiling with sICAM-1 assessment offers a promising non-invasive strategy for TB screening. While sICAM-1 reflects inflammatory activity, methane-based VOC signatures may improve identification of DR-TB.